#VEGF
Think of VEGF as fertiliser for cancer cells.

🤦🏻‍♀️
November 15, 2026 at 11:15 PM
VEGF is stuff that makes new blood vessels grow.

Too much of this stuff and you help tumour cells to grow. So… cancer.
November 15, 2026 at 10:24 PM
INSERM researchers analyzed longitudinal samples from 221 patients recovering from severe COVID.

Persistent VEGF-A signaling was associated with delayed recovery and experimentally triggered release of clotting-related vesicles from endothelial cells.
November 15, 2026 at 12:00 AM
Disappointing -- but not unexpected -- news. This isn't the end of the line for ivonescimab or the PD-1/VEGF bispecific antibody strategy.

www.cancerhealth.com/article/fda-...
FDA Rejects Approval of Ivonescimab for Advanced Lung Cancer
The PD-1/VEGF bispecific antibody delayed disease progression but did not significantly improve survival in a global Phase III study.
www.cancerhealth.com
November 16, 2026 at 9:32 PM
Over 1.1 million injections reveal no increased serious ocular safety risks with combined anti-complement and anti-VEGF therapy in AMD. #AMD #Retina #Complement #AntiVEGF 🔗 buff.ly/6l5GLfl
November 16, 2026 at 10:00 AM
youtube.com/watch?v=VEGF...

Texas has handed Elon Musk’s companies about $1.7 billion in tax breaks and grants, including a massive incentive package for the planned Terafab chip facility. Musk then poured at least $225 million into Texas politics, only to watch Republicans lose control.
He Just Stole BILLIONS From Them...
YouTube video by The Ring of Fire
youtube.com
November 18, 2026 at 6:11 PM
Ophthopedia Update: Incidence and risk factors for epiretinal membrane formation after intravitreal anti-VEGF injection in branch retinal vein occlusion: WHAT IS ALREADY KNOWN ON THIS TOPIC

*

Anti-vascular endothelial growth factor (VEGF) therapy is the… #Ophthalmology #Ophthotwitter #BJO
Incidence and risk factors for epiretinal membrane formation after intravitreal anti-VEGF injection in branch retinal vein occlusion
WHAT IS ALREADY KNOWN ON THIS TOPIC * Anti-vascular endothelial growth factor (VEGF) therapy is the standard treatment for branch retinal vein occlusion (BRVO)-related macular edema. Recently, cases of rapidly progressive epiretinal membranes (ERMs) have been reported after anti-VEGF injections. However, the incidence and risk factors for ERM formation following anti-VEGF therapy remain poorly defined.WHAT THIS STUDY ADDS * This longitudinal cohort study showed that 22% of BRVO eyes developed a new ERM within 1 year after anti-VEGF injection. Post-injection posterior vitreous detachment (PVD) was consistently associated with ERM development in multivariable analyses.HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY * Our findings support closer monitoring of the changes of the vitreoretinal interface after anti-VEGF therapy in eyes with BRVO. Further studies on the mechanisms linking macular edema dynamics, PVD and subsequent ERM formation are needed.Introduction A retinal vein occlusion (RVO) is one of the leading causes of vision reduction in...
dlvr.it
November 17, 2026 at 5:50 PM
New hope for the tiniest preemies. We’re moving from late laser & anti-VEGF to topical propranolol and β3-receptor agonists that actually guide normal retinal vessels. Precision neonatology is here.

link.springer.com/article/10.1...

#ROP #Neonatology #Preterm #Retina
November 18, 2026 at 3:31 AM
🔥WoS #HighlyCitedPaper
Blocking Tumoral #Angiogenesis VEGF/VEGFR Pathway: #Bevacizumab—20 Years of Therapeutic Success and Controversy
✍️by Elena Chitoran, Vlad Rotaru et al.
📊38 citations
Read here📖 www.mdpi.com/2072-6694/17...
#VEGF
November 18, 2026 at 5:17 AM
Intravitreal anti-VEGF therapy is unlikely to cause congestive heart failure (CHF) or other systemic adverse events, according to a review published in the Canadian Journal of Ophthalmology.

Learn more: https://bit.ly/48gJvbu

#AntiVEGF #Retina #CardiovascularSafety
Intravitreal Anti-VEGF Therapy Shows Low Congestive Heart Failure Risk
Intravitreal anti-VEGF agents carry little risk for congestive heart failure, according to a meta-analysis.
bit.ly
November 13, 2026 at 7:47 PM
I LOVE TEXANS 🩵💙

youtube.com/watch?v=VEGF...
Texans Are FURIOUS After Musk Did This...
YouTube video by The Ring of Fire
youtube.com
November 18, 2026 at 11:52 PM
Ophthopedia Update: Weekly Journal Update — November 18, 2026: Access to intravitreal anti-VEGF therapy in Medicare plans, SC-CPC vs micropulse laser surgery, detecting strabismus and amblyopia with AI, highly aspherical lenslets that may slow myopia progression, the failure… #Ophthalmology #News
Weekly Journal Update — November 18, 2026
Access to intravitreal anti-VEGF therapy in Medicare plans, SC-CPC vs micropulse laser surgery, detecting strabismus and amblyopia with AI, highly aspherical lenslets that may slow myopia progression, the failure rates of procedures for secondary glaucoma.
dlvr.it
November 18, 2026 at 5:14 PM
Explore the evolving PD-1/VEGF bispecific landscape with SITC! Discuss survival endpoints, toxicity, mechanistic rationale, regulatory considerations and how comparative benefit, patient access and development risk shape commercial value. Register: https://ow.ly/aMKn5107OaJ
November 18, 2026 at 6:30 PM
𝗧𝗢𝗗𝗔𝗬: ISN-ASON webinar: Management of anemia in cancer patients and VEGF inhibitors related kidney adverse events

🗣️ Verônica Torres, Shveta Motwani, Shuchi Anand, Anushree Shirali
👥 @sabinekaram.bsky.social
🗓️ November 19
🕑 14:00 CET
🔗 Free registration: https://bit.ly/4i6l9XJ
November 19, 2026 at 6:00 AM
The FDA's letter rejecting Summit's ivonescimab says the drug's "modest" benefit doesn't outweigh its toxicity risks.
Updated: FDA letter rejecting Summit cancer drug cites ‘modest’ benefit in data compared with toxicity risk
The FDA’s rejection letter for Summit’s ivonescimab cites VEGF-related toxicities, a potential concern for the PD-1xVEGF bispecific class; Summit downplays it.
endpoints.news
November 18, 2026 at 8:44 PM
Learn how a hypoxic #TumorMicroenvironment impairs bispecific T-cell engager therapy.

Elevated #VEGF secretion drives treatment resistance, while combination treatment with a VEGF inhibitor restores T-cell-mediated #Cytotoxicity. @harvardmed.bsky.social

#STTT #OpenAccess: doi.org/10.1038/s413...
November 12, 2026 at 6:00 AM
Double VEGF/HGF Gene Therapy in Critical Limb Ischemia Complicated by Diabetes Mellitus | SpringerLink
Double VEGF/HGF Gene Therapy in Critical Limb Ischemia Complicated by Diabetes Mellitus | SpringerLink - DF Blog
- Work from Polish colleagues Barc and coworkers report promise with a novel gene therapy approach. Critical leg ischemia (CLI) complicated by diabetes mellitus (DM), which is a very common and danger...
diabeticfootonline.com
November 13, 2026 at 5:41 PM